Tumor DNA test may match patients to smarter cancer drugs
NCT ID NCT02342158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic changes that could be treated with existing drugs. The goal was to see how often this approach leads to a personalized treatment plan.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could show that routine genetic testing of tumors helps doctors choose more effective, personalized treatments for advanced cancer.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures how often a genetic target is found, not whether the matched therapy actually works or improves survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
550 people
The number who actually took part.
- Started
-
Nov 2014
- Finished
-
Aug 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age\>18 years * Histological diagnosis of cancer * Locally advanced or metastatic, biopsiable disease * ECOG Performans Status ≤2 * Affiliation to social security * Signed informed consent. Exclusion Criteria: * Emergency, Individually deprived of liberty or placed under the authority of a tutor * Patients with symptomatic or progressive brain metastasis * Patients who have only bone and/or brain metastases * Pregnant or breastfeeding women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Paoli-Calmettes
Marseille, 13009, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral drug that targets two cancer drivers tested in first human study
- Mitochondria-Targeting drug gamitrinib tested for first time in humans
- Can a Two-Drug combo outsmart advanced cancer?
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- New injectable drug tested for safety in Hard-to-Treat solid tumors
- New antibody drug conjugate tested against advanced cancers